Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 8:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 33,046 matching trials from the live ClinicalTrials.gov search.
Conditions
Rheumatoid Arthritis
Interventions
50 mg LX3305 QD, 100 mg LX3305 QD, 150 mg LX3305 QD, 200 mg LX3305 QD, 250 mg LX3305 QD, 300 mg LX3305 QD, 400 mg LX3305 QD, 250 mg LX3305 BID, 500 mg LX3305 QD, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Diabetes Mellitus and Heart Failure
Interventions
LIK066, Placebo, Empagliflozin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
21
States / cities
Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
Conditions
Hypertension
Interventions
fenofibrate, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
Conditions
Mild Cognitive Impairment, Mild Alzheimer's Disease
Interventions
AZD5213, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 85 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Indio, California • Lomita, California + 10 more
Completed Phase 1 Interventional Accepts healthy volunteers

ANX-188 Thorough QT/QTc Study in Healthy Volunteers

NCT01790087
Conditions
Healthy
Interventions
ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose, Saline, Moxifloxacin
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

NCT01279187
Conditions
Implant
Interventions
Teriparatide, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Type 2 Diabetes Mellitus
Interventions
MB07803, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Los Angeles, California • Walnut Creek, California • Miami, Florida + 20 more
Terminated Not applicable Interventional Results available

Pilot Study of Fosamax in Spinal Cord Injury

NCT01131884
Conditions
Spinal Cord Injury, Osteoporosis
Interventions
Fosamax, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Rochester, New York
Terminated Phase 4 Interventional Results available

Duloxetine for the Treatment of Chronic Pelvic Pain

NCT01451606
Conditions
Pelvis Pain Chronic
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Sepsis
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
Jonathan Sevransky
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Healthy Volunteers
Interventions
ANS-6637 Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Amygdala Neurosciences, Inc.
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Not applicable Interventional Results available

Zinc & Bone Health in Thalassemia: The Think Zinc Study

NCT00459732
Conditions
Thalassemia
Interventions
Zinc, Placebo
Dietary Supplement
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
6 Years to 30 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Oakland, California • San Francisco, California • Philadelphia, Pennsylvania
Conditions
Actinic Keratosis
Interventions
Imiquimod cream 3.75%, Placebo cream
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Fort Meyers, Florida
Conditions
Ocular Myasthenia Gravis
Interventions
Rozanolixizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Scottsdale, Arizona • O'Fallon, Illinois • Amherst, New York + 3 more
Conditions
Systemic Lupus Erythematosus
Interventions
Prednisone, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
13 Years to 65 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
3
States / cities
New Hyde Park, New York • New York, New York • The Bronx, New York
Conditions
Polymyalgia Rheumatica
Interventions
Sarilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
47
States / cities
Avondale, Arizona • Phoenix, Arizona • Tucson, Arizona + 42 more
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers

NCT07531316
Conditions
Healthy Controls
Interventions
Placebo pills for 14-day intervention, VVZ-2471 for 14-day intervention
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Taletrectinib, Placebo
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more
Conditions
Narcotic Addiction, Neonatal Abstinence Syndrome
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 45 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
San Francisco, California • San Jose, California • Stanford, California + 5 more
Conditions
Multiple Sclerosis
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
100
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more
Conditions
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions
recombinant human CC10 (rhCC10), placebo
Drug
Lead sponsor
Clarassance, Inc.
Industry
Eligibility
24 Weeks to 29 Weeks
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Wilmington, Delaware • Baltimore, Maryland • Mineola, New York
Conditions
Myotonic Dystrophy Type 1 (DM1)
Interventions
VX-670, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
San Carlos, California • Gainesville, Florida • Fairway, Kansas + 5 more
Conditions
Systemic Lupus Erythematosus, Healthy Participants
Interventions
BMS-986165, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas